Skip to main content

Omlyclo News

Monthly News Roundup - March 2025

FDA Approves Tremfya for Adults Patients with Active Crohn’s Disease In March, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of Tremfya (guselkumab) for the t...

American Academy of Allergy, Asthma & Immunology, Feb. 28-March 3

The annual meeting of the American Academy of Allergy, Asthma & Immunology was held from Feb. 28 to March 3 in San Diego, drawing clinicians, academicians, allied health professionals, and others i...

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ – Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated a...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Urticaria, Hives, Asthma - Maintenance, Chronic Rhinosinusitis with Nasal Polyps, Asthma, Nasal Polyps

Omlyclo patient information at Drugs.com